Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

@article{Machover1996TwoCP,
  title={Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.},
  author={David Machover and Eduardo Diaz-Rubio and Aimery de Gramont and A Schilf and Julio Gastiaburu and Silvano Brienza and Moshe Itzhaki and Greg Metzger and D N'Daw and Jacques Vignoud and Albert Ses{\'e} Abad and {\'E}ric François and Erik Gamelin and Michel M. Marty and Javier M. Sastre and Jean François Seitz and Marc Ychou},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1996},
  volume={7 1},
  pages={95-8}
}
BACKGROUND Oxaliplatin (L-OHP) is a platinum complex that possesses activity against human and murine cells in vitro and in vivo, including colorectal carcinoma-derived cell lines, and cells that have been selected for resistance to cisplatin. We report two consecutive phase II trials of L-OHP for treatment of patients with advanced colorectal carcinoma. PATIENTS AND METHODS Fifty-eight patients were entered in study I, and 51 patients in study II. All of the patients had tumor progression… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 106 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Oxaliplatin. In Appleton and Lange (eds): Cancer Chemotherapy Handbook

  • RT Dorr, DD VonHoff
  • 1993
2 Excerpts

Similar Papers

Loading similar papers…